$0.09—Stale · unknown old
NASDAQ • Last print unknown ago
$0.09—Stale · unknown old
PLx Pharma Inc. focuses on developing and commercializing proprietary drug delivery technologies, particularly its PLxGuard™ technology aimed at improving the safety and efficacy of NSAIDs. The company primarily operates in the U.S. market, with its flagship product, PLxGuard™-formulated aspirin, targeting patients at risk of gastrointestinal complications.
PLx Pharma generates revenue through the sale of its proprietary NSAID formulations, which are designed to minimize gastrointestinal side effects. The company's competitive advantage lies in its patented delivery technology, which differentiates its products in a crowded market.
FDA approval of new formulations or indications for PLxGuard™
Partnerships or licensing agreements with larger pharmaceutical companies
Market adoption rates of PLxGuard™-formulated products
Changes in regulatory environment affecting drug approvals
Regulatory changes that could impact drug approval processes
Technological disruption in drug delivery systems
Emergence of generic alternatives to PLxGuard™ products
Increased competition from larger pharmaceutical companies with more resources
Liquidity risk due to negative cash flow
Potential need for future capital raises to fund operations
moderate - The demand for pharmaceuticals can be somewhat insulated from economic cycles, but broader healthcare spending trends can impact sales.
Low - As a biotech firm with no debt, interest rates have minimal direct impact, but higher rates could affect overall healthcare spending.
minimal - The company has no debt, reducing exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, with a 1-year return of -95.7%.